FDA — authorised 17 October 2023
- Application: NDA216834
- Marketing authorisation holder: UCB INC
- Local brand name: ZILBRYSQ
- Indication: SOLUTION — SUBCUTANEOUS
- Status: approved
🇺🇸 Zilbrysq in United States
FDA authorised Zilbrysq on 17 October 2023
Marketing authorisations
FDA
- Status: approved
Zilbrysq in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is Zilbrysq approved in United States?
Yes. FDA authorised it on 17 October 2023; FDA has authorised it.
Who is the marketing authorisation holder for Zilbrysq in United States?
UCB INC holds the US marketing authorisation.